Furthermore, microbes have been postulated to exist in basaltic rocks in rinds of altered volcanic glass. All of these conditions could exist in polar regions of Mars today where subglacial volcanism has occurred. Phreatic eruptions
Phreatic eruptions (or steam-blast eruptions) are a type of eruption driven by the expansion of steam. When cold ground or surface water come into contact with hot rock or magma it superheats and explodes, fracturing the surrounding rock and thrusting out a mixture of steam, water, ash, volcanic bombs, and volcanic blocks. The distinguishing feature of phreatic explosions is that they only blast out fragments of pre-existing solid rock from the volcanic conduit; no new magma is erupted. Because they are driven by the cracking of rock strata under pressure, phreatic activity does not always result in an eruption; if the rock face is strong enough to withstand the explosive force, outright eruptions may not occur, although cracks in the rock will probably develop and weaken it, furthering future eruptions.Often a precursor of future volcanic activity, phreatic eruptions are generally weak, although there have been exceptions. Some phreatic events may be triggered by earthquake activity, another volcanic precursor, and they may also travel along dike lines. Phreatic eruptions form base surges, lahars,  avalanches, and volcanic block "rain." They may also release deadly toxic gas able to suffocate anyone in range of the eruption.Volcanoes known to exhibit phreatic activity include:

Mount St. Helens, which exhibited phreatic activity just prior to its catastrophic 1980 eruption (which was itself Plinian).
Febuxostat and its metabolites are eliminated via the urine (49% of the total substance, comprising 3% unchanged febuxostat, 30% febuxostat glucuronide, 13% active metabolites and their glucuronides, and 3% unknown entities) and via the faeces (45%, of which 12% unchanged febuxostat, 1% glucuronide, 25% active metabolites and their glucuronides, and 7% unknown entities). Elimination half-life is five to eight hours. History
Febuxostat was discovered by scientists at the Japanese pharmaceutical company Teijin in 1998. Teijin partnered the drug with TAP Pharmaceuticals in the US and Ipsen in Europe.Ipsen obtained marketing approval for febuxostat from the European Medicines Agency in April 2008, Takeda obtained FDA approval in February 2009, and Teijin obtained approval from the Japanese authorities in 2011. Ipsen exclusively licensed its European rights to Menarini in 2009. Teijin partnered with Astellas for distribution in China and southeast Asia. Society and culture
Cost
In the UK, NICE has found that febuxostat has a higher cost/benefit ratio than allopurinol and on that basis recommended febuxostat as a second-line drug for people who cannot use allopurinol.In 2010, before it became generic in the United States, it cost about US$160 per month as opposed to allopurinol which was about $US14 per month. Trade names
Febuxostat is marketed as Adenuric in Europe, Australia, New Zealand and Pakistan. In Pakistan it is launched by SOLACE Pharmaceuticals a sister subsidiary of SJG, Uloric in the US, Goturic and Goutex in Latin America, Feburic in Japan, Donifoxate in Egypt and is generic in several countries and is available by many names in those countries. References
External links
"Febuxostat".